Prolonged vaginal progesterone supplementation does not improve outcomes for Day 6 frozen blastocyst transfers in oocyte donation cycles
Human Reproduction · 2026
DOI: 10.1093/humrep/deaf205 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, 2026. Verfasst von A Blázquez und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Reproductive Medicine, Eugin Clinic, Barcelona, Spain. Hauptthemen laut MEDLINE: Progesterone, Oocyte Donation, Embryo Transfer. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: theEugin Clinic.
Abstract (Originalsprache)
STUDY QUESTION Does extending vaginal progesterone administration from 5–6 days improve pregnancy outcomes in Day 6 (D6) frozen embryo transfers (FETs) in oocyte donation cycles? SUMMARY ANSWER Prolonging the time of vaginal progesterone supplementation does not improve pregnancy outcomes after D6 FETs in oocyte recipients. WHAT IS KNOWN ALREADY Progesterone is critical for endometrial preparation prior to embryo transfer, but the optimal duration of administration remains unclear. D6 blastocysts are associated with poorer clinical outcomes compared to Day 5 (D5) blastocysts, potentially due to either intrinsic limitations in implantation capacity or a shifted window of implantation (WOI). Extending progesterone administration has been hypothesized to optimize the WOI for D6 blastocysts. STUDY DESIGN, SIZE, DURATION This retrospective cohort study included 485 FETs performed in 420 oocyte donation recipients, conducted from January 2020 to December 2023 in a single IVF center. Participants were divided into two groups based on the duration of progesterone supplementation: 5 days (P + 5, n = 282) and 6 days (P + 6, n = 203). PARTICIPANTS/MATERIALS, SETTING, METHODS The study involved oocyte recipients undergoing single D6 blastocyst transfer following endometrial preparation with vaginal progesterone (800 mg/day). Outcomes were analyzed using univariate and multivariate tests, including logistic regression adjusted for estrogen type and endometrial thickness. MAIN RESULTS AND THE ROLE OF CHANCE Mean recipient age (±SD) was 43.5 (±4.24) years, mean BMI was 25.1, and mean endometrial thickness was 9.6 mm on the day of transfer. Good-quality blastocysts accounted for 35% of all transfers. Clinical outcomes, including biochemical (26.24% vs 26.60%, P = 1.00), clinical (21.99% vs 20.69%, P = 0.83), and ongoing pregnancy (14.54% vs 13.30%, P = 0.79), as well as live birth (14.18% vs 10.66%, P = 0.27) and miscarriage rates (7.45% vs 7.39%, P = 1.00), were all similar between 5 and 6 days of progesterone supplementation, respectively. Adjusted analyses confirmed these findings. LIMITATIONS, REASONS FOR CAUTION The retrospective design warrants careful interpretation. Results are specific to vaginal progesterone in oocyte donation cycles and may not apply to other populations or progesterone delivery methods. Additionally, the D6 embryos analyzed were those that did not reach blastocyst by Day 5 (delayed, poor-prognosis, and typically transferred last), which likely biases outcomes toward lower live birth rates. WIDER IMPLICATIONS OF THE FINDINGS Compromised outcomes following D6 FETs compared to those of D5 blastocysts, likely reflect the intrinsic limitations of slow-developing embryos rather than a misaligned WOI. As prolonged progesterone exposure did not improve outcomes, the WOI may be broader than previously assumed, particularly in oocyte donation programs, where superior embryo quality may mitigate synchronization drawbacks. STUDY FUNDING/COMPETING INTEREST(S) This study was internally funded by the Eugin Clinic, with no external sponsorship. The authors declare no competing interests. TRIAL REGISTRATION NUMBER NA
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Reproductive Medicine, Eugin Clinic, Barcelona, Spain.
- Department of Reproductive Medicine, Eugin Group, Barcelona, Spain.
- Department of Reproductive Medicine, Ghent University Hospital, Ghent, Belgium.
ORCID-Profile: A Blázquez, I Miguel-Escalada, M Popovic
Förderung
- theEugin Clinic
Zitieren
APA
Blázquez, A., Miguel-Escalada, I., Portas-Gómez, L., Guillén-Quílez, J. J., Mataró, D., Popovic, M., & Rodríguez-Aranda, A. (2026). Prolonged vaginal progesterone supplementation does not improve outcomes for Day 6 frozen blastocyst transfers in oocyte donation cycles. Human Reproduction. https://doi.org/10.1093/humrep/deaf205
Vancouver
Blázquez A, Miguel-Escalada I, Portas-Gómez L, Guillén-Quílez JJ, Mataró D, Popovic M, et al. Prolonged vaginal progesterone supplementation does not improve outcomes for Day 6 frozen blastocyst transfers in oocyte donation cycles. Human Reproduction. 2026. doi:10.1093/humrep/deaf205
BibTeX
@article{Blzquez2026,
author = {Blázquez, A and Miguel-Escalada, I and Portas-Gómez, L and Guillén-Quílez, J J and Mataró, D and Popovic, M and Rodríguez-Aranda, A},
title = {Prolonged vaginal progesterone supplementation does not improve outcomes for Day 6 frozen blastocyst transfers in oocyte donation cycles},
journal = {Human Reproduction},
year = {2026},
doi = {10.1093/humrep/deaf205}
}
EUVIMED